ALTIERI, Vincenzo
 Distribuzione geografica
Continente #
NA - Nord America 4.116
EU - Europa 1.306
AS - Asia 535
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 2
AF - Africa 1
Totale 5.970
Nazione #
US - Stati Uniti d'America 4.019
CN - Cina 421
UA - Ucraina 397
DE - Germania 343
IT - Italia 166
RU - Federazione Russa 166
CA - Canada 96
IE - Irlanda 96
FI - Finlandia 77
VN - Vietnam 76
SE - Svezia 20
IN - India 17
TR - Turchia 11
EU - Europa 10
CZ - Repubblica Ceca 7
GB - Regno Unito 5
NL - Olanda 5
ES - Italia 4
FR - Francia 4
GR - Grecia 4
HK - Hong Kong 3
JP - Giappone 3
BE - Belgio 2
BG - Bulgaria 2
RO - Romania 2
SG - Singapore 2
AT - Austria 1
AU - Australia 1
BZ - Belize 1
CH - Svizzera 1
GH - Ghana 1
HU - Ungheria 1
LK - Sri Lanka 1
MT - Malta 1
NZ - Nuova Zelanda 1
OM - Oman 1
PL - Polonia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 5.970
Città #
Ann Arbor 817
Jacksonville 476
Chandler 406
Princeton 333
Wilmington 101
Dublin 96
Ottawa 92
Andover 90
Nanjing 86
Nürnberg 86
Dong Ket 76
Woodbridge 76
Boardman 74
Ashburn 60
Pellezzano 54
Beijing 51
Fairfield 39
Houston 39
Jinan 36
Changsha 35
Shenyang 35
Hebei 24
Tianjin 24
Jiaxing 23
Nanchang 20
Naples 17
Pune 17
Norwalk 15
Zhengzhou 15
Salerno 14
Redwood City 13
Seattle 13
Izmir 11
Hangzhou 9
San Diego 9
Vietri Sul Mare 9
Cambridge 8
Düsseldorf 8
Guangzhou 8
Brno 7
Ningbo 7
Mountain View 6
Taiyuan 6
Taizhou 6
Mestre 5
Boston 4
Edinburgh 4
Guardia Sanframondi 4
Madrid 4
Amsterdam 3
Falls Church 3
Fenton 3
Haikou 3
Lanzhou 3
Marano Di Napoli 3
Avellino 2
Brussels 2
Casalnuovo di Napoli 2
Castellammare Di Stabia 2
Castellammare di Stabia 2
Central District 2
Chengdu 2
Chicago 2
Dearborn 2
Dordrecht 2
Englishtown 2
Hefei 2
Horia 2
Indiana 2
Leawood 2
Napoli 2
New York 2
Paris 2
Phoenix 2
Redmond 2
Rho 2
Shanghai 2
Sofia 2
Stockholm 2
Tappahannock 2
Toronto 2
Andria 1
Ashburton 1
Athens 1
Bilston 1
Bratislava 1
Budapest 1
Calgary 1
Caserta 1
Cremona 1
Dambulla 1
Frankfurt am Main 1
Fuzhou 1
Kamampa 1
Kwun Tong 1
Ladyville 1
Las Vegas 1
Lishui 1
Luzzano 1
Mainz 1
Totale 3.557
Nome #
Ultrasonographic evaluation of urethrovesical junction mobility: correlation with type of delivery and stress urinary incontinence 320
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer 307
Modified glasgow prognostic score is associated with risk of recurrence in bladder cancer patients after radical Cystectomy: A multicenter experience 306
Effect of Non-psychotropic Plant-derived Cannabinoids on Bladder Contractility: Focus on Cannabigerol 293
A randomised study evaluating maintenance schedule in early adjuvant chemotherapy for intermediate risk non-muscle-invasive bladder cancer 87
Are Referral Centers for Non-Muscle-Invasive Bladder Cancer Compliant to EAU Guidelines? A Report from the Vesical Antiblastic Therapy Italian Study 86
Galectin-1 and galectin-3 expression in human bladder transitional-cell carcinomas 85
Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. 80
Concordance and Clinical Significance of Uncommon Variants of Bladder Urothelial Carcinoma in Transurethral Resection and Radical Cystectomy Specimens 78
PTPD1 Supports Receptor Stability and Mitogenic Signaling in Bladder Cancer Cells 78
Cigarette smoking status at diagnosis and recurrence in intermediate-risk non-muscle-invasive bladder carcinoma 78
Prognostic relevance of tumour size in T3a renal cell carcinoma: A multicentre experience 76
Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy 74
A 1-year maintenance after early adjuvant intravesical chemotherapy has a limited efficacy in preventing recurrence of intermediate risk non-muscle-invasive bladder cancer 71
A preoperative clinical prognostic model for non-metastatic renal cell carcinoma 70
Altered expression of specific genes in the HOX network is associated with human bladder transitional cell carcinomas 70
Phase II marker lesion study of 6-week intravesical gemcitabine instillation in patients with low risk non muscle invasive bladder tumours 69
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients 68
Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17 67
Chondroitin sulphate enhances the antitumor activity of gemcitabine and mitomycin-C in bladder cancer cells with different mechanisms 66
Inhibitory Effect of Standardized Cannabis sativa Extract and Its Ingredient Cannabidiol on Rat and Human Bladder Contractility 65
Significance of tumor size in locally advanced renal cell carcinoma (pT3a): An international multicenter experience 65
Zoledronic Acid Increases the Expression of Ndrg1 Gene In Human Androgen-independent Prostate Cancer Pc3 Cells 64
Can pT2 classification for renal cell carcinoma be improved? An international multicenter experience? 64
Evaluation of expression of chromatin assembly factor-1 (CAF-1) p60 in prostatic preneoplastic lesions 64
A nomogram predicting renal cell carcinoma-specific survival in patients with nodal metastases is more accurate than any individual variable 63
Prostate Health Index (phi) Is Able To Discriminate Benign and Precancerous Conditions From Prostate Cancer 62
Endovesical Gemcitabine In Recurrent Previously Treated Non-muscle-invasive Bladder Cancer 62
Cigarette Smoking and Drinking Water Source: Correlation with Clinical Features and Pathology of Superficial Bladder Carcinoma 62
Contemporary Management of Non-muscle Invasive Bladder Cancer At Italian Referral Centres Adopting Eau Guidelines 61
A randomized trial comparing tamoxifen therapy vs. Tamoxifen prophylaxis in bicalutamide-induced gynecomastia 61
Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease: Prognostic indicators of disease-specific survival 60
Calcitonin-producing well-differentiated neuroendocrine carcinoma (carcinoid tumor) of the urinary bladder: case report 60
Docetaxel Retreatment In Docetaxel-pretreated Castration-resistant Prostate Cancer 59
Prognostic significance of T3A renal cell carcinoma with adrenal gland involvement: An international multicenter experience 59
Frequency, clinical presentation and evolution of renal oncocytomas: Multicentric experience from a European database 59
Overexpression of chromatin assembly factor-1 (CAF-1) p60 is predictive of adverse behaviour of prostatic cancer 58
Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study 57
Matrix Metalloproteinase-2 And-9 In the Urine of Prostate Cancer Patients 57
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients 57
Gynecomastia due to hormone therapy for advanced prostate cancer: A report of ten surgically treated cases and a review of treatment options 57
["Classic" vs autolubricant catheterization for endovesicular chemotherapy. Preliminary experience]. 56
Radiocontrast media cause dephosphorylation of Akt and downstream signaling targets in human renal proximal tubular cells 56
Can Gemcitabine Instillation Ablate Solitary Low-Risk Non-Muscle-Invasive Bladder Cancer? Results of a Phase II Marker Lesion Study 55
Distribution of smoking, water resource and other environmental factors in patients affected by superficial bladder cancer 55
Effects of the Erbb1/erbb2 Kinase Inhibitor Gw2974 On the Growth and Nse, Chromogranin A and Osteopontin Content of the Androgen-independent Prostate Cancer Cell Line Pc-3 55
[Imaging diagnosis of non-lymph node metastasis of bladder carcinoma]. 55
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer 54
Pca3 Comparison With Prostate Health Index (phi) In Repeat Biopsy Patients 53
Uracyst Enhances the Antitumor Activity of Drugs In Bladder Cancer Cells 52
CAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers 52
Efficacy of one-year maintenance in early adjuvant chemotherapy for intermediate risk non-muscle-invasive bladder cancer. Results at 24 months of a randomized trial 51
Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy - A multicenter European study 51
[The Rokitansky-Kuster-Hauser syndrome with chromosome XO/XX mosaicism (single pelvic kidney)]. 51
Amelanotic Malignant Melanoma of the Male Urethra: A Potential Diagnostic Pitfall 51
Low-dose oral chemotherapy for hormone refractory prostate carcinoma (HRPC). Estramustine phosphate versus estramustine phosphate and etoposide. A randomised phase II study of GSTU Foundation 50
Oral Chemotherapy in Hormone-Refractory Prostate Carcinoma Patients Unwilling to Be Admitted to Hospital 50
Presence of systemic symptoms is the foremost predictor of mortality in patients with exclusive nodal metastases 50
Phase II trial of gemcitabine, prednisone, and zoledronic acid in pretreated patients with hormone refractory prostate cancer 50
Preoperative insulin-like growth factor-binding protein-3 (IGFBP-3) blood level predicts gleason sum upgrading 49
Drinking water source and cigarette smoking in transitional cell carcinoma of the bladder 49
Out-patient low-dose oral chemotherapy in hormone refractory prostate carcinoma (HRPC) patients unfit for hospital admittance 49
Not traditional prognostic factors in human conventional renal carcinoma. 49
[Erectile dysfunction in kidney transplanted patients]. 49
Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma 48
Hyperexpression of locus C genes in the HOX network is strongly associated in vivo with human bladder transitional cell carcinomas 48
Proposal for revision of the TNM classification system for renal cell carcinoma 48
Effects of the antidepressant St. John's wort (hypericum perforatum) on rat and human vas deferens contractility 48
Standard versus hydrophilic catheterization in the adjuvant treatment of patients with superficial bladder cancer 48
Npc - A Newer Revolutionary Test For Evaluation of Clinical Series. Bladder Cancer 47
Soluble interleukin-6 receptor to interleukin-6 (sIL-6R/IL-6) ratio in serum as a predictor of high Gleason sum at radical prostatectomy 46
Smoking Status, Recurrence Risk and Intravesical Chemotherapy In Non-muscle-invasive Bladder Cancer 46
Prognostic impact of tumor size on pT2 renal cell carcinoma: An international multicenter experience 46
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer 46
Current Evidence of Transurethral En-bloc Resection of Nonmuscle Invasive Bladder Cancer: Update 2016 46
Modulation of BAG3 expression in human normal urothelial cells by Diuron 45
Docetaxel and Carboplatin In Docetaxel Pretreated Castraction-resistant Prostate Cancer: Preliminary Results 44
Effects of the ErbB1/ErbB2 kinase inhibitor GW2974 on androgen-independent prostate cancer PC-3 cell line growth and NSE, chromogranin A and osteopontin content 43
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: A phase II study 43
Prevalence of silent prostatic adenocarcinoma in 165 patients undergone cystoprostatectomy: A retrospective study 43
Prognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: A five year follow-up analysis 41
Predictive accuracy of four prognostic models for non-metastatic renal cell carcinoma after nephrectomy: A comparative study. 41
Local hyperthermia for treatment of advanced prostatic carcinoma: preliminary results. 41
Urotensin Ii Receptor Is Involved In the Regulation of Motility of Prostate Adenocarcinoma Cells and Predicts the Clinical Outcome of Prostate Cancer Patients 39
Preliminary report of a multicentric study on environmental risk factors in Ta-T1 transitional cell carcinoma of the bladder - A study from Gruppo Studi Tumori Urologici (GSTU) Foundation 38
Ki67 in Gleason Pattern 3 as a Marker of the Presence of Higher-Grade Prostate Cancer 34
Role of PA2G4P4 pseudogene in bladder cancer tumorigenesis 30
A serum metabolomic signature for the detection and grading of bladder cancer 30
KPNA2/ERG Coexpression is Associated with Early Recurrence in Advanced Prostate Cancers 26
Choroidal evaluation in patients under alpha-lytic therapy 24
The best prostate biopsy sampling system—fusion and systematic biopsy: A single center experience 22
Nomogram for predicting the likelihood of postoperative surgical complications in patients treated with partial nephrectomy: a prospective multicentre observational study (the RECORd 2 project) 17
Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? 16
Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project) 10
Totale 6.041
Categoria #
all - tutte 14.598
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.598


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019348 0 0 0 0 0 0 0 0 81 96 99 72
2019/20201.169 289 73 163 61 78 4 86 7 85 170 120 33
2020/2021782 152 84 92 10 88 6 83 3 81 8 89 86
2021/2022566 2 0 1 6 7 8 12 30 94 86 68 252
2022/2023975 95 55 16 114 137 231 0 101 139 0 65 22
2023/2024265 44 68 16 20 40 32 8 36 1 0 0 0
Totale 6.041